Development of new multi-valent vaccine systems against Candida pathogens

Project description

A new vaccine against fungal pathogens

Treatment of fungal infections poses a significant medical challenge due to the few available drugs and the associated resistance. Efforts so far to develop vaccines have been met with limited success. VacCan is an EU-funded project that aims to develop a novel vaccine against Candida albicans, the leading cause of fungal infections in humans. Vaccine design will combine three proteins of the fungus, thereby providing multiple antigens against which a more robust immune response can be generated. The VacCan approach will advance vaccine research and pave the way for more effective management of fungal pathogens.

Fields of science

• medical and health sciences › health sciences › infectious diseases
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• natural sciences › biological sciences › microbiology › mycology
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

KING'S COLLEGE LONDON

Net EU contribution

€ 212 933,76

Address

Strand
WC2R 2LS London
United Kingdom

Region

London › Inner London — West › Westminster

Activity type

Higher or Secondary Education Establishments

Links

Other funding

€ 212 933,76